DSGN - Design Therapeutics Inc Year-over-year net earnings per share growth for the last 12 months
The future of Design Therapeutics (DSGN) relies on the verification of gene-targeting methods and patent protection. Quarterly EPS growth reflects the dynamics of the fundamental cycle, where the indicator settled at -7.70. Business success is based on the efficiency of molecule delivery and the search for partners, while current R&D expenses have already been priced in by the market prior to the publication of test results.
Design Therapeutics (DSGN) - metric breakdowns and financial figures
- share price and consensus valuation forecast:
- market capitalization statistics:
- book capitalization indicators:
- company total debt and liquidity indicators:
Debt to Equity Design Therapeutics|DSGN - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital designtx.com|DSGN - Company Aggregate Debts|Debt to Book Capitalization Ratio Design Corp|DSGN - Long-Term Liabilities|Company Short-Term Debts Design Therapeutics|Quick Liquidity Indicator designtx.com
- earnings and valuation multiples indicators:
DSGN - Net Profit|Future Profit Design Therapeutics|DSGN - Market Price to Net Income Ratio|Forward P/E Multiple designtx.com|DSGN - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Design Therapeutics, Inc.|DSGN - Operating profit before deduction of amortization|Earnings per share for the last twelve months Design Therapeutics|DSGN - Net earnings per share for the last four quarters|Quarterly EPS earnings growth designtx.com|DSGN - Earnings per share growth this year|Net earnings per share growth forecast for next year Design Therapeutics
- sales revenue and business income indicators:
Initial company analysis:Design Therapeutics
Design Therapeutics operates as a biotech startup funded by raised investments in the absence of current revenue. Under these conditions, the calculated earnings per share trend reflects the burn rate of capital allocated to clinical development. This metric measures operational efficiency by neutralizing time lags between quarterly reports. An upward trend in quarterly earnings per share growth confirms the fundamental stability of the business, while a decline signals risks of accelerated liquidity depletion.
Competing companies
TEM: Quarterly EPS earnings growth|Qiagen Corp - Year-over-year earnings per one share growth for the last 12 months|IONS (Ionis Pharmaceuticals) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months RGEN (Repligen)|Quarterly EPS earnings growth RNA|CRSP (CRISPR Therapeutics) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth WGS (GeneDx Holdings Corp.)|RARE: Year-over-year earnings per share growth for the last 12 months|BEAM - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months sarepta.com|TWST: Quarterly EPS earnings growth|TXG - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Intellia|Earnings per share growth in annualized terms for the last twelve months Stoke Therapeutics STOK|Quarterly EPS earnings growth BLFS|Wave Life Sciences - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth MAZE (Maze Therapeutics, Inc.)|Quarterly EPS earnings growth Sionna Pharma SION|Prime Medicine Bio - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months TSHA (Taysha)|QURE: Quarterly EPS earnings growth|MGTX - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months RGNX|SLDB: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months ocugen.com (OCGN)|Year-over-year net earnings per share change for the last twelve months PacBio Corp|Year-over-year earnings per share growth for the last twelve months Benitec Biopharma BNTC|Quarterly EPS earnings growth rocketpharma.com RCKT|4DMT - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Lexeo Therapeutics, Inc.|Korro Bio (KRRO) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months EDIT|SLN (Silence Therapeutics plc) - Quarterly EPS earnings growth|proqr.com (PRQR) - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months CDXS (Codexis Bio)|SGMO - Earnings per share growth in annualized terms for the last twelve months|Nautilus Biotechnology, Inc. - Year-over-year net earnings per share growth for the last 12 months|Net earnings per share growth for the trailing year Metagenomi, Inc|Precision BioSciences - Quarterly EPS earnings growth|Net earnings per share growth for the trailing year generationbio.com (GBIO)|Boundless Bio Inc (BOLD) - Year-over-year earnings per share growth for the last twelve months|Exicure Inc. - Year-over-year earnings per one share growth for the last 12 months|IMNN (imunon.com) - Quarterly EPS earnings growth|Phio Pharmaceuticals - Year-over-year net earnings per share trend for the last twelve months|Year-over-year earnings per share growth for the last twelve months Mustang Bio Corp (MBIO)|Quarterly EPS earnings growth TransCode (RNAZ)|Quarterly EPS earnings growth BNGO (bionanogenomics.com)|APDN (Applied DNA Sciences Inc) - Year-over-year net earnings per share trend for the last twelve months|BLUE - Year-over-year earnings per share growth for the last twelve months|ImmunoPrecise Antibodies Ltd. (IPA) - Year-over-year net earnings per share growth for the last 12 months|OMGA (Omega) - Year-over-year net earnings per share growth for the last 12 months|singulargenomics.com (OMIC) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months RGLS|Syros (SYRS) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months telesisbio.com (TBIO)|TCON - Earnings per share growth in annualized terms for the last twelve months|Quarterly EPS earnings growth UBX (Unity Biotechnology Inc.)
